BioSpace News Archive

BioCapital

Biotech In-Demand Jobs: Statisticians and Mathematicians

As the first part of a six-part series describing the hottest careers in the biopharma industry, we discussed the rewarding career of genetic counselor. Now, let’s take a look at the high in demand biopharma careers of biostatistician and biometrician.

October 18, 2019
·
5 min read
·
Don Potochny
FDA

Genentech’s Xofluza Approved for People at High Risk of Developing Flu-Related Complications

Genentech’s flu medication Xofluza won a new indication for the treatment of acute, uncomplicated influenza in people 12 years of age and older who have been symptomatic for less than 48 hours and are at high risk of flu-related complications.

October 18, 2019
·
2 min read
·
Alex Keown
BioMidwest

OSU Scientists Unlock Less Wasteful Way to Synthesize Drugs

A new method of synthesizing molecule arrangements in medicine could change the way many drugs, including the PARP inhibitor Zejula, a treatment for ovarian cancer, are produced.

October 18, 2019
·
2 min read
·
Alex Keown
Business

Drugging the Undruggable: A Talk with Plexium’s Swamy Vijayan

Plexium is focused on developing therapeutics that influence E3 ligases that can degrade proteins, even the undruggable ones. The company’s founder and chief executive officer Kandaswamy “Swamy” Vijayan, took time out to speak with BioSpace about the company and its technology platform, DELPHe.

October 18, 2019
·
4 min read
·
Mark Terry
Biotech Bay

Invitae Questions Accuracy of 23andMe’s Cancer Tests in Certain Populations

A competitor, Invitae Corporation, presented a poster at the American Society of Human Genetics (ASHG) annual meeting that essentially accuses 23andMe’s tests of completing missing a cancer-causing DNA variant in some ethnic groups.

October 18, 2019
·
3 min read
·
Mark Terry
Biotech Beach

New Insights into Huntington’s Disease Could Lead to New Treatment Strategies

New research by researchers at the University of California Los Angeles into the role of astrocytes, star-shaped brain cells, in the disease, may lead to new treatment strategies.

October 18, 2019
·
3 min read
·
Mark Terry
Drug Development

J&J’s Tremfya Shows Extended Success in Treating Plaque Psoriasis

Janssen Pharmaceutical of Johnson & Johnson released new long-term data from the open-label period of its Phase III VOYAGE 1 clinical trial.

October 18, 2019
·
2 min read
·
Mark Terry
Drug Development

Clinical Catch-Up: October 14-18

Last week was busy for clinical trial news. Here’s a look.

October 18, 2019
·
6 min read
·
Mark Terry
Business

Merck to Eliminate Nearly 500 Jobs in Early 2020 Due to Shifting R&D Focus

According to the report, the majority of the cuts will occur in the company’s Human Health Division and are expected to begin Jan. 3 and conclude Jan. 16, 2020.

October 18, 2019
·
2 min read
·
Alex Keown
Policy

FDA Action Alert: Foamix, Eton, Adamis and RedHill

We round out the month of October and start the month of November with four PDUFA dates on the U.S. Food and Drug Administration’s calendar. Here’s a look.

October 18, 2019
·
3 min read
·
Mark Terry